QuantaMatrix Multiplex Assay Platform
QMAP (QuantaMatrix Multiplex Assay Platform) is a multi-marker diagnostic technology using coded microparticles (Microdisk). This allows various codes to be engraved into a 50 μm microdisk and each code can be used to detect different types of biomarkers. Using this technology, several biomarkers can be identified simultaneously in a single test. Therefore, it has higher accuracy and medical value compared to conventional single marker diagnosis.
Multi-marker analysis based on coded Microdisk technology
QMAP technology forces target probes to be coupled to multi-coded microdisk, allowing each code to uniquely combine different types of biomarkers. It confirms the type of marker through the bright field image, analyzes the intensity of mean fluorescence intensity (MFI) through fluorescence image, and measures positivity or the amount of biomarkers. This technology can be widely used in various kinds of diagnostic markers such as proteins, DNA, and RNA in the blood. This multi-marker diagnostic platform consists of analysis system (QMAP 2.0) and automatic system (QMIA).
The surface of microdisk is coated with solid silica material, which is excellent in physicochemical durability. In addition, bio-analysis using silica surface has been widely used for many years with known and validated analytical methods for protein, DNA, and RNA analysis. There are currently more than 1,000 physically feasible codes, which can diagnose more codes simultaneously than other multi-marker diagnostic technology.
For QMAP 2.0, which is an analysis only instrument, the test protocol is conducted outside, until the image analysis phase. QMIA, on the other hand, is a fully automated instrument where all process and tests are automatically performed after sample loading. QMAP 2.0 is suitable for research and development stages and non-automated testing environments, and QMIA is an automated system optimized for routine testing environments in various diagnostic labs.
Molecular immunoassay system
Equipment that constitutes these multi-marker diagnostic platforms include: analysis only system (QMAP2.0), and automated analysis system (QMIA).
QMIA is a fully automated sample-to-answer system that performs all testing processes after sample loading. The QMIA instrument is optimized for repeated testing of various diagnostic kits. All the user has to do is to transfer the centrifugally separated whole blood into the sample, and when the sample and reagent are mounted and the system is initiated, the instrument automatically completes all the work until the result are available. It is a high- throughput device that can process 23~96 samples in one operation depending on the type of kits. It is therefore suitable for high throughput diagnostic testing. The total test time depends on the analytical conditions of the application kit and can take anywhere from 1 to 4 hours. QMIA with multi-marker technology enables early diagnosis of Alzheimer's dementia.
The QMAP2.0 instrument automatically analyzes microdisks that have completed all inspection procedures. It is based on 96 well-plate, and can automatically analyze the results of up to 96 samples at a time. Each takes about 20 seconds to analyze, and 96 samples can be analyzed within 30 minutes. QMAP 2.0 is particularly useful in developing diagnostic kits before applying to automated platforms. In addition, it is a powerful tool for analyzing experiment conditions for various markers, as well as for screening for candidate markers.